VXRT News and Press, Vaxart Inc. From 04/27/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Decelerating momentum and limited profitability prospects make these stocks analysts hate. Bed Bath & Beyond ( BBBY ): The meme stock continues to burn cash due to supply chain problems. Netflix ...

Many companies that successfully developed effective coronavirus vaccines are reaping the benefits and generating millions -- sometimes billions -- in sales from their products. However, other players are still looking to get in the game. Two notable companies still hoping to make a den...

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET. ...

FinancialBuzz.com News Commentary New York, NY (4/5/2022) – Recent data regarding the pandemic has revealed that hospitalizations and death rates are rising once again. Nevertheless, the number of people dying from COVID-19 is relatively low when compared with earlier this or las...

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...

Vaxart (NASDAQ: VXRT) and Moderna (NASDAQ: MRNA) have a lot in common. Both companies are working on coronavirus vaccines, and both claim to have an advanced technology platform that'll enable them to open new frontiers in medicine and public health. Whereas Moderna's ti...

Vaxart (NASDAQ: VXRT) surged early in the coronavirus vaccine race. It climbed 2,400% in the first six months of 2020. That's as investors bet it would bring a potentially game-changing candidate to market. But Vaxart's program didn't move as quickly as those of vaccine market leade...

Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022. Vaxart's oral vaccine technology is unique and holds great potential with several advantages like easier route of administration, room temperature stability, and greater poten...

Vaxart press release (NASDAQ:VXRT): Q4 GAAP EPS of -$0.17 misses by $0.01. Revenue of $0.07M (-80.6% Y/Y) misses by $0.11M. For further details see: Vaxart GAAP EPS of -$0.17 misses by $0.01, revenue of $0.07M misses by $0.11M

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, ca...